Stockwatch: Good money after bad news?
This article was originally published in Scrip
Executive Summary
The usual playbook for fund-raising at biotechnology companies is that soon after the announcement of a positive clinical trial or a regulatory approval, the company will raise money in order to either complete, either the regulatory filing or to launch the product, respectively.